Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF
April 23, 2001
- DIAGNOSTICS NEWS IN BRIEF
April 23, 2001
- NEW PRODUCTS NEWS IN BRIEF
April 23, 2001
- Kureha, Sankyo Tie Up for Joint Development of CXCR4 Blocker
April 23, 2001
- Patients"Success Rate Increases to Record High in 2000: Malpractice Lawsuits
April 23, 2001
- Market Share of Generics Should Be Considered in Pricing of Long-listed Drugs: JMA
April 23, 2001
- LDP's Commission Lists 4 Points of Discussion for NHI Pricing Reform
April 23, 2001
- Mr MRto Enable Physicians to Easily Access Information: Mr Tanimura of So-net M3
April 23, 2001
- REGULATORY NEWS IN BRIEF
April 23, 2001
- MEDICAL DEVICE NEWS IN BRIEF
April 23, 2001
- Marketing of Half-strength Preparations of Digoxin Expected
April 23, 2001
- Fujisawa, ORIX Capital Establishes New Investment Fund
April 23, 2001
- OBITUARY
April 23, 2001
- Eisai Subscribes to Incyte Genomics"Databases
April 23, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 23, 2001
- Mochida, Maruishi to Jointly Develop Capsaicin-based Cream
April 23, 2001
- Lilly's Gemzar Approved for Pancreatic Cancer Treatment
April 23, 2001
- Pharmacia's Zyvox Approved
April 23, 2001
- First Int'l GL for COPD Published
April 23, 2001
- GSK Obtains Import Approval for Alkeran for Injection 50mg
April 23, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…